ArticleFrontiers in pharmacology2023

A type II cannabis extract and a 1:1 blend of Δ(9)-tetrahydrocannabinol and cannabidiol display distinct antinociceptive profiles and engage different endocannabinoid targets when administered into the subarachnoid space.

Besma Benredjem et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.